Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Paper

Association of Single Nucleotide Polymorphisms in the Eosinophil Peroxidase Gene with Allergic Rhinitis in the Czech Population

Hrdlickova B. · Izakovicova-Holla L.I.

Author affiliations

Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic

Related Articles for ""

Int Arch Allergy Immunol 2009;150:184–191

Do you have an account?

Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: June 03, 2008
Accepted: January 15, 2009
Published online: May 13, 2009
Issue release date: September 2009

Number of Print Pages: 8
Number of Figures: 0
Number of Tables: 6

ISSN: 1018-2438 (Print)
eISSN: 1423-0097 (Online)

For additional information: https://www.karger.com/IAA

Abstract

Background: Eosinophil peroxidase (EPO) gene codes a cationic protein released from the specific granules of activated eosinophils. Eosinophil granulocytes play a central role in the protection of organisms against parasites. They are also regarded as key effector cells in allergic inflammation. We attempted to determine the polymorphisms in the EPO gene typical for the Czech population and to analyze their associations with allergic rhinitis and its intermediary phenotypes. Methods: We sequenced all 12 exons of the EPO gene, and selected variants were subsequently analyzed by polymerase chain reaction and restriction fragment length polymorphism methods in a case-control study comprising a total of 613 subjects (319 controls and 294 patients with rhinitis). Results: In total, 5 polymorphisms (–1710T/C and –1710T/CTCC, 2649T/C, 3097A/G and 3979A/G) were found in the EPO gene. Polymorphisms 2649T/C and 3097A/G were in complete linkage disequilibrium (D′ = 1 for both groups), and both of them were in a strong disequilibrium with the 3979A/G variant (D′ = 0.801 for controls, D′ = 0.848 for rhinitics). Consequently, these 3 polymorphisms were studied in association with the allergic phenotype. In a single locus analysis, only 3979A/G single nucleotide polymorphism was marginally significantly associated with rhinitis (p = 0.030, pcorr > 0.05). This polymorphism also showed a marginal association with total serum IgE levels (loge IgE, mean ± SD: genotypes GG = 2.60 ± 1.20; GA = 2.47 ± 1.88; AA = 2.38 ± 1.49; p < 0.05). Furthermore, significant differences in haplotype frequencies between patients and healthy subjects were observed (p < 0.05). Conclusions: Our study supports the hypothesis that genetic variability in the EPO gene may contribute to the susceptibility to allergic rhinitis (or related phenotypes) in the Czech population.

© 2009 S. Karger AG, Basel


References

  1. Bachert C, van Cauwenberge P, Olbrecht J, van Schoor J: Prevalence, classification and perception of allergic and nonallergic rhinitis in Belgium. Allergy 2006;61:693–698.
  2. Bousquet J, van Cauwenberge P, Khaltaev N; Aria Workshop Group; World Health Organization: Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108(suppl 5):S147–S334.
  3. Beasley R: Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: the International Study of Asthma and Allergies in Childhood/ISAAC/Steering Committee. Lancet 1998;351:1225–1232.
  4. Wang DY: Risk factors of allergic rhinitis: genetic or environmental? Ther Clin Risk Manag 2005;1:115–123.
  5. Malerba G, Pignatti PF: A review of asthma genetics: gene expression studies and recent candidates. J Appl Genet 2005;46:93–104.
  6. Brasch-Andersen C, Haagerup A, Børglum AD, Vestbo J, Kruse TA: Highly significant linkage to chromosome 3q13.31 for rhinitis and related allergic diseases. J Med Genet 2006;43:e10.
  7. Haagerup A, Bjerke T, Schøitz PO, Binderup HG, Dahl R, Kruse TA: Allergic rhinitis – a total genome-scan for susceptibility genes suggests a locus on chromosome 4q24–q27. Eur J Hum Genet 2001;9:945–952.
  8. Halonen M, Stern DA: Predicting the course of asthma. Allergy Asthma Proc 2006;27:328–331.
  9. Malerba G, Lindgren CM, Xumerle L, Kiviluoma P, Trabetti E, Laitinen T, Galavotti R, Pescollderungg L, Boner AL, Kere J, Pignatti PF: Chromosome 7p linkage and GPR154 gene association in Italian families with allergic asthma. Clin Exp Allergy 2007;37:83–89.
  10. Kim KR, Cho SH, Choi SJ, Jeong JH, Lee SH, Park CW, Tae K: TAP1 and TAP2 gene polymorphisms in Korean patients with allergic rhinitis. J Korean Med Sci 2007;22:825–831.
  11. Garcia-Martin E, Garcia-Menaya J, Sanchez B, Martinez C, Rosendo R, Agundez JA: Polymorphisms of histamine-metabolizing enzymes and clinical manifestations of asthma and allergic rhinitis. Clin Exp Allergy 2007;37:1175–1182.
  12. Holgate ST: Genetic and environmental interaction in allergy and asthma. J Allergy Clin Immunol 1999;104:1139–1146.
  13. Busse WW, Rosenwasser LJ: Mechanisms of asthma. J Allergy Clin Immunol 2003;111(suppl 3):S799–S804.
  14. Saeed W, Badar A, Hussain MM, Aslam M: Eosinophils and eosinophil products in asthma. J Ayub Med Coll Abbottabad 2002;14:49–55.
  15. Venge P: Monitoring the allergic inflammation. Allergy 2004;59:26–32.
  16. Sakamaki K, Tomonaga M, Tsukui K, Nagata S: Molecular cloning and characterization of a chromosomal gene for human eosinophil peroxidase. J Biol Chem 1989;264:16828–16836.
  17. Ten RM, Pease LR, McKean DJ, Bell MP, Gleich GJ: Molecular cloning of the human eosinophil peroxidase. Evidence for the existence of a peroxidase multigene family. J Exp Med 1989;169:1757–1769.
  18. Giembycz MA, Lindsay MA: Pharmacology of the eosinophil. Pharmacol Rev 1999;51:213–340.
  19. Thomas EL, Bozeman PM, Jefferson MM, King CC: Oxidation of bromide by the human leukocyte enzymes myeloperoxidase and eosinophil peroxidase. Formation of bromamines. J Biol Chem 1995;270:2906–2913.
  20. Wu W, Chen Y, d’Avignon A, Hazen SL: 3-Bromotyrosine and 3,5-dibromotyrosine are major products of protein oxidation by eosinophil peroxidase: potential markers for eosinophil-dependent tissue injury in vivo. Biochemistry 1999;38:3538–3548.
  21. Wu W, Chen Y, Hazen SL: Eosinophil peroxidase nitrates protein tyrosyl residues. Implications for oxidative damage by nitrating intermediates in eosinophilic inflammatory disorders. J Biol Chem 1999;274:25933–25944.
  22. Wu W, Samoszuk MK, Comhair SA, Thomassen MJ, Farver CF, Dweik RA, Kavuru MS, Erzurum SC, Hazen SL: Eosinophils generate brominating oxidants in allergen-induced asthma. J Clin Invest 2000; 105:1455–1463.
  23. Nakagawa T, Ikemoto T, Takeuchi T, Tanaka K, Tanigawa N, Yamamoto D, Shimizu A: Eosinophilic peroxidase deficiency: identification of a point mutation (D648N) and prediction of structural changes. Hum Mutat 2001;17:235–236.
  24. Romano M, Dri P, Dadalt L, Patriarca P, Baralle FE: Biochemical and molecular characterization of hereditary myeloperoxidase deficiency. Blood 1997;90:4126–4134.
  25. Romano M, Baralle FE, Patriarca P: Expression and characterization of recombinant human eosinophil peroxidase. Impact of the R286H substitution on the biosynthesis and activity of the enzyme. Eur J Biochem 2000;267:3704–3711.
  26. Nakamura H, Miyagawa K, Ogino K, Endo T, Imai T, Ozasa K, Motohashi Y, Matsuzaki I, Sasahara S, Hatta K, Eboshida A: High contribution contrast between the genes of eosinophil peroxidase and IL-4 receptor α-chain in Japanese cedar pollinosis. J Allergy Clin Immunol 2003;112:1127–1131.
  27. Nakamura H, Higashikawa F, Miyagawa K, Nobukuni Y, Endo T, Imai T, Ozasa K, Motohashi Y, Matsuzak I, Sasahara S, Hatta K, Ogino K, Eboshida A: Association of single nucleotide polymorphisms in the eosinophil peroxidase gene with Japanese cedar pollinosis. Int Arch Allergy Immunol 2004;135:40–43.
  28. Hanifin JM, Rajka G: Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1980;92:44–47.
  29. Buckova D, Holla LI, Vasku A, Znojil V, Vacha J: Lack of association between atopic asthma and the tumor necrosis factor alpha-308 gene polymorphism in a Czech population. J Investig Allergol Clin Immunol 2002;12:192–197.
  30. Lewontin RC: On measures of gametic disequilibrium. Genetics 1988;120:849–852.
  31. Carlson MG, Peterson CG, Venge P: Human eosinophil peroxidase: purification and characterization. J Immunol 1985;134:1875–1879.
  32. Erpenbeck VJ, Hohlfeld JM, Petschallies J, Eklund E, Paterson CG, Fabel H, Krug N: Local release of eosinophil peroxidase following segmental allergen provocation in asthma. Clin Exp Allergy 2003;33:331–336.
  33. Stephens JC, Schneider JA, Tanguay DA, Choi J, Acharya T, Stanley SE, Jiang R, Messer CJ, Chew A, Han JH, Duan J, Carr JL, Lee MS, Koshy B, Kumar AM, Zhang G, Newell WR, Windemuth A, Xu C, Kalbfleisch TS, Shaner SL, Arnold K, Schulz V, Drysdale CM, Nandabalan K, Judson RS, Ruano G, Vovis GF: Haplotype variation and linkage disequilibrium in 313 human genes. Science 2001;293:489–493.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: June 03, 2008
Accepted: January 15, 2009
Published online: May 13, 2009
Issue release date: September 2009

Number of Print Pages: 8
Number of Figures: 0
Number of Tables: 6

ISSN: 1018-2438 (Print)
eISSN: 1423-0097 (Online)

For additional information: https://www.karger.com/IAA


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.